Stock LLM Wiki

260624_2303_ubs_umc

更新 2026-06-24

PDF 原檔:260624_2303_ubs_umc_original.pdf

原始內容

UMC

Time to shine with structural shift in supply

Mature foundry and UMC fundamentals turning around fast

YTD we have maintained an anti-consensus Buy on UMC, as we are constructive on mature foundry fundamentals improving in coming years. Industry dynamics are now strengthening much faster than our expectation. 1) On the supply side, large foundry makers continue to streamline resources on mature nodes. Our industry studies suggest UMC is seeing an increasing number of new product opportunities as clients diversify. 2) As for China, our view is the expansion for mature nodes should slow down from here as large players re-focus on leading edge. 3) Mature foundry pricing has inflected upward YTD. We believe UMC could raise prices by 5-10% for selected products in H226, followed by a 10% increase for its broader product range in early 2027. An improving product mix should also lift blended ASP . We forecast UMC's blended wafer price to steadily increase by 10-11% CAGR in 2026-30E.

Potential new opportunity if TSMC were to reallocate 28nm capacity in Taiwan

On industry supply, based on our industry surveys, we believe it is possible that TSMC might re-pivot parts of its Fab 15 for leading edge nodes such as N3. TSMC may reallocate the N28 capacity at Fab 15 P1 (50kwpm) in 2027 for its Germany expansion of N28/12. If this were to happen, we would see it as positive for UMC, as it could drive: 1) tighter supply-demand in 28/40nm; and 2) overflow opportunities as TSMC reduces supply in Taiwan. We expect UMC's 28nm utilisation to exceed 90% in 2027E, especially with several new wins, including Sony's ISP and Omnivision's auto CIS.

Intel collaboration and silicon photonics likely to contribute to 2028 earnings

UMC's 12nm collaboration with Intel has attracted steady client interest. We expect the business to be margin-accretive, contributing 6% of operating profit by 2028E. Firstwave products for mass production include TV controllers, connectivity and high-speed I/O, likely followed by OLED drivers in the second wave. The collaboration should focus on 12nm mass production for now (see Figure 1 u O r I n t e l p a s h i c o y for more analysis). On silicon photonics, although UMC is a latecomer, it should benefit from tight industry supply. We anticipate pluggables to contribute more meaningfully by 2028E, with a potential sales opportunity of US$0.2-0.3bn (2% of 2028E sales), assuming a 10% share of the US$23bn TAM. See Figure 2 i S l c o n p t h f u r d y T A M a e v b s g w m F G - Figure 4 T o w r e S m i c n d t u ' s b l h v p a k for industry commentary on silicon photonics.

Valuation: reiterate Buy, raising price target from NT$108 to NT$230

We raise 2027/28E EPS by 18%/55% on more favourable supply-demand, price hikes, a better product mix, and more robust margin expansion. With earnings growth reaccelerating, we shift our valuation from a 3x PB to a 25x 2027-28E PE, raising our price target from NT$108 to NT$230. We think a multiple at the high end of its 7-28x historical PE range is justified, given 1) the industry is undergoing a structural, not cyclical, shift in fundamentals; and 2) we forecast a 32% earnings CAGR in 2027-30E.

Highlights (NT$m) 12/23 12/24 12/25 12/26E 12/27E 12/28E 12/29E 12/30E
Revenues 222,533 232,303 237,553 273,854 346,239 447,135 510,723 564,912
EBIT (UBS) 57,891 51,613 43,949 56,547 94,417 162,248 191,828 213,492
Net earnings (UBS) 60,990 47,211 41,716 58,213 84,034 143,922 172,176 193,168
EPS (UBS, diluted) (NT$) 4.93 3.80 3.34 4.66 6.73 11.52 13.78 15.46
DPS (net) (NT$) 3.02 2.87 2.34 3.26 4.71 8.07 9.65 10.83
Net (debt) / cash 57,781 29,957 37,691 70,342 125,463 214,852 289,517 360,102
Profitability/valuation 12/23 12/24 12/25 12/26E 12/27E 12/28E 12/29E 12/30E
EBIT (UBS) margin% 26.0 22.2 18.5 20.6 27.3 36.3 37.6 37.8
ROIC (EBIT)% 31.1 20.5 16.2 21.4 36.8 65.3 78.4 87.4
EV/EBITDA (UBS core) x 4.4 5.2 4.3 16.4 12.0 8.3 7.2 6.5
P/E (UBS, diluted) x 9.9 13.4 13.3 36.5 25.3 14.8 12.3 11.0
Equity FCF (UBS) yield% 0.2 1.0 9.1 2.6 3.4 5.7 7.6 8.2
Dividend yield (net)% 6.2 5.6 5.3 1.9 2.8 4.7 5.7 6.4
Equities Equities Equities Equities
Taiwan Semiconductors Taiwan Semiconductors Taiwan Semiconductors Taiwan Semiconductors
12-month rating 12-month rating 12-month rating Buy
12m price target 12m price target 12m price target NT$230.00 Prior : NT$108.00
Price (23 Jun 2026) Price (23 Jun 2026) Price (23 Jun 2026) NT$171.50
RIC: 2303.TW BBG: 2303 TT RIC: 2303.TW BBG: 2303 TT RIC: 2303.TW BBG: 2303 TT RIC: 2303.TW BBG: 2303 TT
Trading data and key metrics Trading data and key metrics Trading data and key metrics Trading data and key metrics
52-wk range 52-wk range 52-wk range NT$171.50-40.40
Market cap. Shares o/s Market cap. Shares o/s Market cap. Shares o/s NT$2,159b/US$68.3b 12,588m (ORD)
Free float Free float Free float 89%
Avg. daily volume ('000) Avg. daily volume ('000) Avg. daily volume ('000) 241,464
Avg. daily value (m) Avg. daily value (m) Avg. daily value (m) NT$26,080.8
Common s/h equity (12/26E) Common s/h equity (12/26E) Common s/h equity (12/26E) NT$420b
P/BV (12/26E) 5.1x
Net debt to EBITDA (12/26E) Net debt to EBITDA (12/26E) Net debt to EBITDA (12/26E) NM
EPS (UBS, diluted) (NT$) EPS (UBS, diluted) (NT$) EPS (UBS, diluted) (NT$)
From To %ch Cons.
12/26E 4.56 4.66 2 4.47
12/27E 5.72 6.73 18 5.42
12/28E 7.43 11.52 55 6.53
Sunny Lin Analyst sunny.lin@ubs.com 7346
+886-2-8722 Ryan Sun Associate
Analyst ryan-za.sun@ubs.com +886-2-8722 7267
Christine Chen Associate Analyst christine.chen@ubs.com +886-2-8722 7352

Thesis Map UBS Research THESIS MAP a guide to our thinking and what´s where in this report

Pivotal Questions

UBS VIEW

EVIDENCE

WHAT´S PRICED IN?

Upside/Downside Spectrum

Company Description

Q: Can UMC's blended ASP rebound in 2026 after a two-year downtrend?

Yes. We think UMC's blended ASP can improve in 2026 and beyond, due to: 1) mature foundry supply-demand improving; 2) more rational pricing competition among Chinese foundries; and 3) a stronger restocking cycle, given very clean inventory downstream. Rising memory costs remain an overhang and may continue to impact consumer demand and restocking in H226. However, with a stable ASP , improving product mix, and utilisation upside, we forecast UMC's sales to grow 15% in 2026E and 26% in 2027E, after the muted 2% growth in 2025.

Q: Will Chinese competition undermine UMC's stabilising capacity utilisation?

No. We believe industry competition will be manageable, at least in 2026-27. UMC's 28nm utilisation has remained resilient with held above 80% through the industry downturn in 2023-25. UMC's differentiated 22nm can also support its market share, with greater power efficiency than the competition. Meanwhile, UMC's key customers are likely to maintain balanced procurement across regions to diversify geopolitical risk, supporting continued demand. Over the longer term, collaboration with Intel on 12nm FinFET should differentiate UMC from Chinese peers.

UMC is our top pick in the mature foundry space, considering: 1) its technological position, with differentiated 22nm offering greater power efficiency, the need for its customers to maintain balanced procurement across regions amid geopolitical risks, and its partnership with Intel over the longer term; and 2) improving earnings momentum in 2026, with rising utilisation, stabilising pricing dynamics and slower depreciation growth.

Among mature foundries, most (UMC, GlobalFoundries, Vanguard, SMIC and Hua Hong) have guided for relatively stable like-for-like pricing from Q225. Most non-Chinese foundries have also guided for more stable sales growth in coming quarters, suggesting some demand upside from broad-based restocking. TSMC's comments on mature foundry business reallocation also read positively for the mature foundry industry. If TSMC drives meaningful optimisation of mature capacity for advanced packaging, we would view UMC as a key beneficiary of order outflow in upcoming years.

We think UMC's YTD re-rating may reflect increasing optimism about TSMC's capacity reallocation benefits, Intel's partnership opportunities, along with a healthier supply-demand outlook and UMC's GM recovery in 2026E and beyond. At 15x 2028E PE, UMC's valuation is at a discount to the upper end of its 14-22x NTM PE range in the previous upcycle (2021-early 2022). The premium over its 14x PE historical mean likely bakes in the improvement we expect in UMC's earnings momentum from 2026E.

FF91E06FE22A5CC269BA119985F0B1ECC852A6D7_260624_ubs_umc_001
Value drivers (2027/28E) Utilisation rate Wafer ASP growth throughout the year Gross margin
NT$280.00 upside 94.1%/98.2% 15%/19% 38.2%/46.9%
NT$230.00 base 91.8%/97.0% 11%/15% 37.3%/45.4%
NT$110.00 downside 88.2%/91.9% 5%/6% 35.1%/42.3%

Source: UBS estimates

Founded in 1980, UMC is a leading dedicated foundry service provider, with annual capacity of around 11.6m 8-inch equivalent wafers as of 2025. In 2025, communications applications accounted for 41% of its total revenue, consumer electronics 31%, computer applications 12% and other 16%.

Figure 1: Our Intel partnership scenario analysis

Scenario analysis 2028E
Wafer volume (kwpm) 25.0
N12 wafer ASP (US$) 5,500
Total wafer revenue (US$mn) 1,650
%recognition by UMC 50%
Sales to UMC (US$mn) 825
%of UMC sales 5.8%
Gross profit (US$mn) 371
Assumed GM 45%
%of UMC gross profit 5.8%
OPEX 58
as %of sales 7%
Operating income 314
OPM 38.0%
Operating profit to UMC (US$mn) 314
Operating profit to UMC (NT$mn) 9,916
%to UMC's operating profit 6.1%

Source: Company data, UBS estimates

Figure 2: Silicon photonic foundry TAM and revenue by leaders including Tower Semiconductor and GlobalFoundries

US$ 2024 2025 2026F 2027F 2028F 2029F 2030F 2031F 2032F Implied CAGR
Silicon Photonics Wafer SAM ~$700m ~$6.5bn ~45% CAGR FY26-32F
US$ Silicon Photonics Revenue 2024 2025 2026F 2027F 2028F 2029F 2030F 2031F 2032F Implied CAGR
Tower Semiconductor $106m $228m Q1 grew 3x yoy $1.3Bn
GlobalFoundries ~$100m ~$200m $400m target >$1Bn exit run rate ~$2Bn ~50% CAGR FY26-30F

Source: Company data and company targets, UBS. Note: SiPh wafer SAM source from Nov 2025 GFS presentation .

Figure 3: GlobalFoundries' bullish view on the silicon photonic market

May 2026 "We've accelerated our targets [for silicon photonics]: US$1bn run rate by the exit of 2028. We're targeting US$2bn of revenue in 2030 as we target share gains in pluggables and the ramp in near and co-packaged optics. The demand for power is insatiable across all of the markets we serve." - Sam Franklin, CFO of GFS
Feb 2026 "We believe we are on a path to reach a US$1bn run rate revenue level for silicon photonics by the end of 2028, a substantial acceleration from our prior objective " - Tim Breen, CEO of GFS
Nov 2025 GFS announced acquisition (closed in February 2026) of AMF, a pureplay SiPh foundry based in Singapore. This acquisition will expand GF's silicon photonics technology portfolio, production capacity and research and development in Singapore, complementing its existing technology capabilities in the US and unlocking new market opportunities with a broader set of datacenter and communication technologies - GFS Nov 25 press release
Nov 2025 " We see this [silicon photonics] as a tremendous opportunity over time for GlobalFoundries, and speaks to both our history in silicon photonics, as well as our analog mixed signal differentiation. Again, back to that point. So [we are] very, very bullish about this opportunity over time." - Tim Breen, CEO of GFS
Sep 2025 ' Silicon photonics technology is essential for AI infrastructure. As data moves faster and workloads grow more complex, the ability to move information with greater speed, precision and power efficiency is now fundamental to AI datacenters and advanced telecom networks,' - Tim Breen, CEO of GFS

Source: Company data, UBS

Figure 4: Tower Semiconductor's bullish view on the silicon photonic market

May 2026 "So if you just look again, the growth of SiPho ports is 4.5x from 2025 to 2028, and that entire amount of port growth is added from 2028 to 2030. So a lot of room for a tremendous amount of SiPho growth ." - Russell C. Ellwanger, CEO of TSEM
May 2026 "Our expansion remains on track to grow SiPho capacity 5 times from the base of our Q4 2025 wafer revenue shipments by the end of this year, 2026." - Russell C. Ellwanger, CEO of TSEM
Feb 2026 "In our recent announcement with NVIDIA, the insatiable demand for compute bandwidth in both scale-up and scale-out architectures and Towers' exceptional ability to scale the capacity flawlessly in partnership with our customer has made 1.6 terabyte per second, the fastest- growing silicon photonics node in the industry to-date, with Tower being by far the majority supplier of 1.6T silicon PICs. The partnership announced with NVIDIA, as with all our direct module customers, underscores our commitment to deliver best-in-class technology and the manufacturing agility required to meet such an exceptional demand trajectory ." - Russell C. Ellwanger, CEO of TSEM
Feb 2026 We also see co-package optics as a substantially incremental opportunity for us in the coming years, as optics gets adopted and scale up interconnects, as well as XPU to high bandwidth memory interconnects that are today largely copper. - Russell C. Ellwanger, CEO of TSEM
Feb 2026 We continue to work with several customers on dense wavelength division multiplexing laser sources, which are a critical component of many CPO implementations and can significantly expand our served optical market by now including the laser source. - Russell C. Ellwanger, CEO of TSEM

Source: Company data, UBS

Figure 5: Industry P/BV vs. ROE

FF91E06FE22A5CC269BA119985F0B1ECC852A6D7_260624_ubs_umc_002

Source: Company data, UBS estimates

Figure 6: UMC's operating metrics

Q126 Q226E Q326E Q426E Q127E Q227E Q327E Q427E 2022 2023 2024 2025 2026E 2027E 2028E
Capacity (8" eq.) Sequential Change Shipment (8" eq.) 2,886 2,297 2,936 2% 2,949 0% 2,983 1% 3,017 1% 3,051 1% 3,118 2% 3,152 1% 10,031 6% 10,519 5% 11,305 7% 11,617 3% 11,754 1% 12,337 5% 13,113 6%
(%) -2% 2,466 2,566 2,625 2,655 2,745 3% 2,931 2,994 9,945 7,189 7,754 8,710 9,954 11,325 12,721
Sequential Change (%) 3% 7% 4% 2% 1% 7% 2% 1% -28% 8% 12% 14% 14% 12%
Utilization rate (%) 80% 84% 87% 88% 88% 90% 94% 95% 99% 68% 69% 75% 85% 92% 97%
ASP (US$) Sequential Change (%) 840 -5% 861 2% 878 2% 896 2% 923 3% 950 3% 979 3% 1,008 3% 928 20% 994 7% 928 -7% 869 -6% 870 0% 967 11% 10,947 1,111 15%
Wafer Revenue (US$mn) Total Revenue (NT$mn) 1,930 2,123 2,253 2,352 2,449 2,609 2,869 3,019 9,231 7,147 7,196 7,567 8,658 14,136
Revenue %at 28nm 61,038 67,160 71,276 74,379 77,477 82,528 90,747 95,486 278,705 222,533 232,303 237,553 273,854 346,239 447,135
Capex (US$mn) 396 300 300 504 300 300 300 600 24% 2,632 31% 2,928 2,739 1,517 1,500 1,500 1,500
Capex/Revenue (%) 21% 14% 67,160 13% 71,276 21% 74,379 12% 11% 10% 20% 29% 278,705 41% 38% 232,303 20% 237,553 17% 273,854 14% 346,239 11%
Revenue (NT$mn) Sequential Change EPS (NT$) 61,038 -1.2% 6.1% 4.4% 77,477 4.2% 82,528 6.5% 90,747 10.0% 95,486 5.2% 222,533 -20.2% 4.4% 26.4% 447,135 29.1%
10.0% 1.01 1.21 2.02 30.8% 7.09 2.3% 15.3% 4.66 6.73
1.29 1.15 1.25 1.58 1.88 4.93 3.80 3.34 37.3% 11.52
Gross margin (%) 29.2% 31.0% 31.8% 32.3% 38.7% 39.5% 45.1% 31.2% 45.4%
Operating margin (%) 18.5% 20.3% 21.4% 22.1% 33.2% 22.7% 37.1% 26.8% 28.8% 29.9% 37.4% 34.9% 26.0% 32.6% 22.2% 29.0% 18.5% 20.6% 27.3% 36.3%

Source: Company data, UBS estimates

."

Figure 7: Revisions to UBS earnings estimates

New New New Old Old Old Change Change Change
(NT$m) 2026E 2027E 2028E 2026E 2027E 2028E 2026E 2027E 2028E
Revenue 273,854 346,239 447,135 272,190 315,403 358,179 1% 10% 25%
- YoY chg (%) 15% 26% 29% 15% 16% 14%
Revenue (US$m) 8,658 10,947 14,136 8,605 9,972 11,324 1% 10% 25%
- YoY chg (%) 14% 26% 29% 14% 16% 14%
Gross profit 85,315 129,103 202,824 84,457 114,327 140,897 1% 13% 44%
- Gross margin 31.2% 37.3% 45.4% 31.0% 36.2% 39.3%
Operating profit 56,547 94,417 162,248 55,756 81,000 104,237 1% 17% 56%
- Operating margin 20.6% 27.3% 36.3% 20.5% 25.7% 29.1%
Net profit 58,213 84,034 143,922 56,949 71,423 92,820 2% 18% 55%
- Net margin 21.3% 24.3% 32.2% 20.9% 22.6% 25.9%
UBS EPS (NT$) 4.66 6.73 11.52 4.56 5.72 7.43 2% 18% 55%
- YoY chg (%) 39% 44% 71% 36% 25% 30%

Source: UBS estimates

Figure 8: UBS vs consensus earnings estimates

UBSe UBSe UBSe Consensus Consensus Consensus Difference Difference Difference
(NT$m) 2026E 2027E 2028E 2026F 2027F 2028F 2026E 2027E 2028E
Revenue 273,854 346,239 447,135 273,607 317,789 351,107 0% 9% 27%
- YoY chg 15% 26% 29% n.a. 16% 10%
Gross profit 85,315 129,103 202,824 85,571 107,638 124,448 0% 20% 63%
- Gross margin 31.2% 37.3% 45.4% 31.3% 33.9% 35.4%
Operating profit 56,547 94,417 162,248 58,205 77,565 92,079 -3% 22% 76%
- Operating margin 20.6% 27.3% 36.3% 21.3% 24.4% 26.2%
Net profit 58,213 84,034 143,922 58,628 69,840 82,584 -1% 20% 74%
- Net margin 21.3% 24.3% 32.2% 21.4% 22.0% 23.5%
EPS (NT$) 4.66 6.73 11.52 4.68 5.58 6.71 -1% 20% 72%
- YoY chg 39% 44% 71% n.a. 19% 20%

Source: Visible Alpha consensus estimates, UBS estimates

Figure 9: UBS earnings forecasts

(NT$m) 2025 Q126 Q226E Q326E Q426E 2026E Q127E Q227E Q327E Q427E 2027E 2028E 2029E 2030E
Revenue 237,553 61,038 67,160 71,276 74,379 273,854 77,477 82,528 90,747 95,486 346,239 447,135 510,723 564,912
- YoY chg (%) 2% 5% 14% 21% 20% 15% 27% 23% 27% 28% 26% 29% 14% 11%
- QoQ chg (%) - -1% 10% 6% 4% - 4% 7% 10% 5% - - - -
Revenue (US$m) 7,567 1,930 2,123 2,253 2,352 8,658 2,449 2,609 2,869 3,019 10,947 14,136 16,147 17,860
- YoY chg (%) 5% 10% 11% 16% 19% 14% 27% 23% 27% 28% 26% 29% 14% 11%
- QoQ chg (%) - -2% 10% 6% 4% - 4% 7% 10% 5% - - - -
Gross profit 68,906 17,818 20,818 22,682 23,996 85,315 25,739 30,594 35,089 37,681 129,103 202,824 237,001 263,849
- Gross margin 29.0% 29.2% 31.0% 31.8% 32.3% 31.2% 33.2% 37.1% 38.7% 39.5% 37.3% 45.4% 46.4% 46.7%
Operating profit 43,949 11,276 13,623 15,227 16,420 56,547 17,604 22,137 26,171 28,505 94,417 162,248 191,828 213,492
- Operating margin 18.5% 18.5% 20.3% 21.4% 22.1% 20.6% 22.7% 26.8% 28.8% 29.9% 27.3% 36.3% 37.6% 37.8%
Non-op profit 5,699 5,367 1,190 1,654 1,347 9,557 803 1,031 1,481 1,131 4,446 7,071 10,731 13,764
Pre-tax profit 49,648 16,644 14,813 16,881 17,767 66,104 18,408 23,168 27,652 29,636 98,863 169,320 202,559 227,256
Net profit 41,717 16,171 12,591 14,349 15,102 58,213 15,647 19,693 23,504 25,190 84,034 143,922 172,176 193,168
UBS EPS (NT$) 3.34 1.29 1.01 1.15 1.21 4.66 1.25 1.58 1.88 2.02 6.73 11.52 13.78 15.46
- YoY chg (%) - QoQ chg (%) -12% - 108% 61% 41% -22% -4% 14% 50% 5% 39% - -3% 4% 56% 26% 64% 19% 67% 7% 44% - 71% - 20% - 12% -

Source: Company data, UBS estimates

Figure 10: UMC's 12-month-forward P/BV (x)

FF91E06FE22A5CC269BA119985F0B1ECC852A6D7_260624_ubs_umc_003

Source: LSEG, UBS estimates

Figure 11: UMC's 12-month-forward PE (x)

FF91E06FE22A5CC269BA119985F0B1ECC852A6D7_260624_ubs_umc_004

Source: LSEG, UBS estimates

Company Description

Company Description

Founded in 1980, UMC is a leading dedicated foundry services provider, with annual capacity of around 10.0m 8-inch equivalent wafers as of 2022. In 2022, communication applications accounted for 45% of its total revenue, consumer electronics 26%, computer applications 15% and other 14%.

Industry Outlook

While industry excess capacity may continue in the near term, we believe the competitive dynamics stabilised in 2025, based on the consumer restocking opportunity and less significant Chinese expansion. We believe the pace of capacity growth in China likely peaked in 2024 and may start to moderate in 2025-26. On the demand side, we are optimistic about structural positives stemming from silicon content growth on technology spec upgrades (eg, 5G, Wi-Fi, OLED and camera image sensors/image signal processing) and new applications (eg, IoT and auto/ industrial).

Revenue by technology (2025)

FF91E06FE22A5CC269BA119985F0B1ECC852A6D7_260624_ubs_umc_005

Source: Company data, UBS

Revenue by application (2025)

FF91E06FE22A5CC269BA119985F0B1ECC852A6D7_260624_ubs_umc_006

Source: Company data, UBS

UMC (2303.TW)

Income Statement (NT$m) 12/23 12/24 12/25 12/26E %ch 12/27E %ch 12/28E 12/29E 12/30E
Revenues 222,533 232,303 237,553 273,854 15.3 346,239 26.4 447,135 510,723 564,912
Gross profit 77,744 75,654 68,906 85,315 23.8 129,103 51.3 202,824 237,001 263,849
EBITDA (UBS) 98,375 99,780 103,208 122,068 18.3 162,885 33.4 226,143 249,479 265,289
Depreciation & amortisation (40,484) (48,168) (59,259) (65,521) -10.6 (68,468) -4.5 (63,895) (57,651) (51,797)
EBIT (UBS) 57,891 51,613 43,949 56,547 28.7 94,417 67.0 162,248 191,828 213,492
Associates & investment income 6,913 411 2,418 3,015 24.7 200 -93.4 200 200 200
Other non-operating income 2,559 2,022 2,344 4,816 105.5 400 -91.7 400 400 400
Net interest 3,549 2,174 937 1,726 84.3 3,846 122.8 6,471 10,131 13,164
Exceptionals (incl goodwill) 0 0 0 0 - 0 - 0 0 0
Pre-tax profit 70,912 56,220 49,648 66,104 33.1 98,863 49.6 169,320 202,559 227,256
Tax (9,472) (9,113) (8,113) (7,946) 2.1 (14,829) -86.6 (25,398) (30,384) (34,088)
Profit after tax 61,440 47,106 41,535 58,158 40.0 84,034 44.5 143,922 172,176 193,168
Preference dividends 0 0 0 0 - 0 - 0 0 0
Minorities (450) 105 182 54 -70.0 0 - 0 0 0
Extraordinary items 0 0 0 0 - 0 - 0 0 0
Net earnings (local GAAP) 60,990 47,211 41,716 58,213 39.5 84,034 44.4 143,922 172,176 193,168
Net earnings (UBS) 60,990 47,211 41,716 58,213 39.5 84,034 44.4 143,922 172,176 193,168
Tax rate (%) 13.4 16.2 16.3 12.0 -26.4 15.0 24.8 15.0 15.0 15.0
Per Share (NT$) 12/23 12/24 12/25 12/26E %ch 12/27E %ch 12/28E 12/29E 12/30E
EPS (UBS, diluted) 4.93 3.80 3.34 4.66 39.5 6.73 44.4 11.52 13.78 15.46
EPS (local GAAP, diluted) 4.93 3.80 3.34 4.66 39.5 6.73 44.4 11.52 13.78 15.46
EPS (UBS, basic) 4.93 3.80 3.34 4.66 6.73 44.4 11.52 15.46
DPS (net) (NT$) 3.02 39.5 4.71 44.4 8.07 13.78
Cash EPS (UBS, diluted) 1 8.20 2.87 7.67 2.34 3.26 39.5 22.5 12.21 23.2 16.64 9.65 18.40 10.83 19.61
Book value per share 28.67 30.16 8.09 30.17 9.91 33.59 11.3 37.05 10.3 43.86 49.58 55.40
Average shares (diluted) 12,371 12,436 12,485 12,491 0.1 12,491 0.0 12,491 12,491 12,491
Balance Sheet (NT$m) 12/23 12/24 12/25 12/26E %ch 12/27E %ch 12/28E 12/29E 12/30E
Cash and equivalents Other current assets 132,554 84,244 105,000 84,678 110,660 94,123 140,395 116,552 26.9 23.8 195,517 145,275 39.3 24.6 284,905 176,475 359,570 194,044 430,155 213,791
Total current assets 216,797 189,678 204,783 461,380 553,614 643,946
Net tangible fixed assets 239,123 279,059 271,395 256,947 25.5 340,791 32.6 215,820 205,614 201,262
Net intangible fixed assets 4,373 4,154 4,743 253,293 -6.7 -6.0 232,270 4,460 -8.3 0.0 4,460 4,460 4,460
Investments / other assets 98,894 97,309 98,075 4,460 116,467 18.8 124,833 7.2 134,161 139,089 144,445
559,187 570,201 702,354 11.3
Total assets 578,996 631,166 9.0 815,821 902,777 994,113
Trade payables & other ST liabilities 69,478 55,750 60,001 60,601 1.0 65,536 8.1 68,309 70,257 74,199
Short term debt Total current liabilities 29,537 19,510 27,597 22,888 83,489 -17.1 -4.7 22,888 0.0 5.9 22,888 91,198 22,888 22,888 97,088
Long term debt 99,015 45,236 75,260 55,533 87,598 45,372 47,165 4.0 88,424 47,165 0.0 47,165 93,145 47,165 47,165
Other long term 55,358 22.3 103,905 28.4 129,501 143,078
liabilities Preferred shares 0 61,222 0 66,170 80,937 - 0 - 0 0 157,827 0
Total liabilities (incl pref shares) 199,608 192,016 0 199,141 0 211,591 6.3 239,494 13.2 267,863 283,388 302,080
Common s/h equity Minority interests 359,238 377,928 379,768 419,540 10.5 462,824 0.0 36 619,353 691,998
341 257 87 36 -59.2 36 10.3 547,923 36 36
Total liabilities & equity 559,187 570,201 578,996 631,166 9.0 702,354 11.3 815,821 902,777 994,113
Cash Flow (NT$m) 12/23 12/24 12/25 12/26E %ch 12/27E %ch 12/28E 12/29E 12/30E
Net income (before pref divs) 60,990 47,211 41,716 58,213 39.5 84,034 44.4 143,922 63,895 172,176 193,168
Depreciation & amortisation 40,484 48,168 59,259 65,521 10.6 68,468 4.5 (17,076) 57,651 51,797
Net change in working capital 916 (2,889) 1,617 (5,228) - (15,785) -201.9 (9,707) (10,965)
Other operating (10,301) 2,350 (4,299) (15,543) -261.6 (16,369) -5.3 (20,679) (10,842) (10,196)
Operating cash flow 92,089 (91,150) 94,840 98,293 102,963 4.8 120,348 16.9 170,061 (47,445) 209,278 223,803
Tangible capital expenditure 0 (88,423) (47,616) 0 (47,445) 0.4 (47,445) 0.0 (47,445) 0 (47,445)
Intangible capital expenditure 0 0 - 0 - 0 0
Net (acquisitions) & disposals 0 0 0 - 0 0 - - 0 0 0 0
Other investing (6,636) 2,482 0 (5,538) (8,832) -59.5 0 0
Investing cash flow (97,787) (85,941) (53,154) (56,277) -5.9 (47,445) 15.7 (47,445) (47,445) (47,445)
Equity dividends paid (45,018) (37,586) (35,788) 0 (29,202) 18.4 (40,749) -39.5 - (58,823) 0 (100,745) 0 (120,523) 0
Share issues / (buybacks) 0 0 - 0
Other financing 0 (11,445) (1,265) (1,596) 13,879 - 22,968 65.5 25,596 13,577 14,750
Change in debt & pref shares 27,377 (337) (1,812) (3,044) -68.0 0 - 0 0 0
Financing cash flow (29,086) (39,188) (39,195) (18,368) 53.1 (17,781) 3.2 (33,227) (87,168) (105,773) 70,585
Cash flow inc/(dec) in cash (34,783) (30,289) 5,944 28,318 1,417 376.5 - 55,122 0 94.7 -100.0 89,388 0 74,665 0 0
FX / non cash items (6,482) 2,736 (284) 29,735 NM 55,122 85.4 89,388
Balance sheet inc/(dec) in cash (41,265) 5,660 74,665
(27,553) 70,585

Source: Company accounts, UBS estimates. (UBS) metrics use reported figures which have been adjusted by UBS analysts. 1 Cash EPS (UBS, diluted) is calculated using UBS net income adding back depreciation and amortization.

UMC (2303.TW)

Valuation (x) 12/23 12/24 12/25 12/26E 12/27E 12/28E 12/29E 12/30E
P/E (local GAAP, diluted) 9.9 13.4 13.3 36.8 25.5 14.9 12.4 11.1
P/E (UBS, diluted) 9.9 13.4 13.3 36.8 25.5 14.9 12.4 11.1
P/CEPS 5.9 6.7 5.5 17.3 14.0 10.3 9.3 8.7
Equity FCF (UBS) yield% 0.2 1.0 9.1 2.6 3.4 5.7 7.5 8.2
Dividend yield (net)% 6.2 5.6 5.3 1.9 2.7 4.7 5.6 6.3
P/BV 1.7 1.7 1.5 5.1 4.6 3.9 3.5 3.1
EV/revenues (core) 2.0 2.3 1.9 7.4 5.7 4.3 3.6 3.1
EV/EBITDA (UBS core) 4.4 5.2 4.3 16.5 12.1 8.4 7.3 6.6
EV/EBIT (core) 7.5 10.1 10.2 35.7 20.9 11.7 9.5 8.2
EV/OpFCF (core) 53.6 61.8 7.8 29.1 19.8 11.8 9.5 8.4
EV/op. invested capital 2.3 2.1 1.6 7.6 7.7 7.7 7.4 7.2
Enterprise value (NT$m) 12/23 12/24 12/25 12/26E 12/27E 12/28E 12/29E 12/30E
Market cap. 602,268 639,158 556,509 2,158,869 2,158,869 2,158,869 2,158,869 2,158,869
Net debt (cash) (92,068) (43,869) (33,824) (54,016) (97,902) (170,158) (252,184) (324,809)
Buy out of minorities 342 299 172 61 36 36 36 36
Pension provisions/other 0 0 0 0 0 0 0 0
Total enterprise value 510,542 595,588 522,857 2,104,914 2,061,002 1,988,747 1,906,720 1,834,095
Non core assets (74,255) (72,487) (75,373) (86,828) (86,784) (86,739) (86,695) (86,650)
Core enterprise value 436,288 523,100 447,484 2,018,086 1,974,218 1,902,008 1,820,025 1,747,445
Growth (%) 12/23 12/24 12/25 12/26E 12/27E 12/28E 12/29E 12/30E
Revenue (20.2) 4.4 2.3 15.3 26.4 29.1 14.2 10.6
EBITDA (UBS) (33.7) 1.4 3.4 18.3 33.4 38.8 10.3 6.3
EBIT (UBS) (44.5) (10.8) (14.8) 28.7 67.0 71.8 18.2 11.3
EPS (UBS, diluted) (30.4) (23.0) (12.0) 39.5 44.4 71.3 19.6 12.2
Net DPS (17.0) (5.2) (18.4) 39.5 44.4 71.3 19.6 12.2
Margins & Profitability (%) 12/23 12/24 12/25 12/26E 12/27E 12/28E 12/29E 12/30E
Gross profit margin 34.9 32.6 29.0 31.2 37.3 45.4 46.4 46.7
EBITDA margin 44.2 43.0 43.4 44.6 47.0 50.6 48.8 47.0
EBIT (UBS) margin 26.0 22.2 18.5 20.6 27.3 36.3 37.6 37.8
Net earnings (UBS) margin 27.4 20.3 17.6 21.3 24.3 32.2 33.7 34.2
ROIC (EBIT) 31.1 20.5 16.2 21.4 36.8 65.3 NM NM
ROIC post tax 26.5 17.2 13.4 18.7 31.3 55.5 66.6 74.3
ROE (UBS) 17.6 12.8 11.0 14.6 19.0 28.5 29.5 29.5
Capital structure & Coverage (x) 12/23 12/24 12/25 12/26E 12/27E 12/28E 12/29E 12/30E
Net debt / EBITDA (0.6) (0.3) (0.4) (0.6) (0.8) (1.0) (1.2) (1.4)
Net debt / total equity% (16.1) (7.9) (9.9) (16.8) (27.1) (39.2) (46.7) (52.0)
Net debt / (net debt + total equity)% (19.1) (8.6) (11.0) (20.1) (37.2) (64.5) (87.8) NM
Net debt/EV% (18.0) (7.4) (6.5) (2.6) (4.8) (8.6) (13.2) (17.7)
Capex / depreciation% NM 183.6 80.4 72.4 69.3 74.3 82.3 91.6
Capex / revenue% EBIT / net interest NM - NM - 20.0 - 17.3 - 13.7 - 10.6 - 9.3 - 8.4 -
Dividend cover (UBS) 1.6 1.3 1.4 1.4 1.4 1.4 1.4 1.4
Div. payout ratio (UBS)% 61.3 75.5 70.0 70.0 70.0 70.0 70.0 70.0
12/25
Revenues by division (NT$m) 12/23 12/24 12/26E 12/27E 12/28E 12/29E 12/30E
Foundry 222,533 232,303 237,553 273,854 346,239 447,135 510,723 564,912
Others 0 0 0 0 0 0 0 0
Total 222,533 232,303 237,553 273,854 346,239 447,135 510,723 564,912
EBIT (UBS) by division (NT$m) 12/23 12/24 12/25
others 57,891 51,613 12/26E 12/27E 12/28E 12/29E 12/30E
Foundry and Others 0 0 43,949 0 56,547 0 94,417 0 162,248 0 191,828 0 213,492 0
Total 57,891 51,613 43,949 56,547 94,417 162,248 191,828 213,492

Source: Company accounts, UBS estimates. (UBS) metrics use reported figures which have been adjusted by UBS analysts.

Forecast returns

Forecast price appreciation 34.1%
Forecast dividend yield 1.9%
Forecast stock return 36.0%
Market return assumption 6.2%
Forecast excess return 29.8%

Company Description

Founded in 1980, UMC is a leading dedicated foundry services provider, with annual capacity of around 10.0m 8-inch equivalent wafers as of 2022. In 2022, communication applications accounted for 45% of its total revenue, consumer electronics 26%, computer applications 15% and other 14%.

Valuation Method and Risk Statement

We base our price target for UMC on a PE methodology.

In our view, UMC faces a variety of risks, including rapidly changing technology, intense competition, high capital investment and cyclical demand. The company has a history of paying out stock options to employees, which could dilute earnings.

Quantitative Research Review

UBS Global Research publishes a quantitative assessment of its analysts' responses to certain questions about the likelihood of an occurrence of a number of short term factors in a product known as the 'Quantitative Research Review'. The views for this month can be found below. Views contained in this assessment on a particular stock reflect only the views on those short term factors which are a different timeframe to the 12-month timeframe reflected in any equity rating set out in this note. For previous responses please make reference to (i) previous UBS Global Research reports; and (ii) where no applicable research report was published that month, the Quantitative Research Review which can be found at https://neo.ubs.com/quantitative, or contact your UBS sales representative for access to the report or the Quantitative Research Team on ubs-quant-answers@ubs.com. A consolidated report which contains all responses is also available and again you should contact your UBS sales representative for details and pricing or the Quantitative Research Team on the email above.

UMC

Question Response
1. Is the industry structure facing the firm likely to improve or deteriorate over the next six months? Rate on a scale of 1-5 (1 = getting worse, 3 = no change, 5 = getting better, N/A = no view) 4
2. Is the regulatory/government environment facing the firm likely to improve or deteriorate over the next six months? Rate on a scale of 1-5 (1 = getting tougher 3 = no change, 5 = getting better, N/A = no view) 3
3. Over the last 3-6 months in broad terms have things been improving/no change/getting worse for this stock? Rate on a scale of 1-5 (1 = getting a lot worse, 3 = not much change, 5 = getting a lot better, N/A = no view) 4
4. Relative to the current CONSENSUS EPS forecast, is the next company EPS update likely to lead to: (1 = negative surprise vs consensus, 3 = in-line with consensus, 5 = positive surprise vs consensus expectations, N/A = no view) 4
5. What's driving the difference?
6. Relative to YOUR current earnings forecast, is there relatively greater risk at the next earnings result of:(1 = downside skew risk to earnings, 3 = equal upside or downside risk to earnings, 5 = upside skew risk to earnings, N/A = no view) 3
7. What's driving the difference?
8. Is there an upcoming catalyst for the company over the next three months?
9. Is there an actual or approximate date for the catalyst?
10. Is the catalyst date an actual or approximate date?
11. What is the catalyst?

Required Disclosures

This document has been prepared by UBS Securities Pte. Ltd., Taipei Branch, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates, including former Credit Suisse AG and its subsidiaries, branches and affiliates are referred to herein as "UBS".

For information on the ways in which UBS manages conflicts and maintains independence of its UBS Global Research product; historical performance information; certain additional disclosures concerning UBS Global Research recommendations; and terms and conditions for certain third party data used in research report, please visit https://www.ubs.com/disclosures. Unless otherwise indicated, information and data in this report are based on company disclosures including but not limited to annual, interim, quarterly reports and other company announcements. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission. UBS acts or may act as principal in the debt securities (or in related derivatives) that may be the subject of this report. This recommendation was finalized on: 23 June 2026 01:33 PM GMT. UBS has designated certain UBS Global Research department members as Derivatives Research Analysts where those department members publish research principally on the analysis of the price or market for a derivative, and provide information reasonably sufficient upon which to base a decision to enter into a derivatives transaction. Where Derivatives Research Analysts coauthor research reports with Equity Research Analysts or Economists, the Derivatives Research Analyst is responsible for the derivatives investment views, forecasts, and/or recommendations. Quantitative Research Review: UBS Global Research publishes a quantitative assessment of its analysts' responses to certain questions about the likelihood of an occurrence of a number of short term factors in a product known as the 'Quantitative Research Review'. Views contained in this assessment on a particular stock reflect only the views on those short term factors which are a different timeframe to the 12-month timeframe reflected in any equity rating set out in this note. For the latest responses, please see the Quantitative Research Review Addendum at the back of this report, where applicable. For previous responses please make reference to (i) previous UBS Global Research reports; and (ii) where no applicable research report was published that month, the Quantitative Research Review which can be found at https://neo.ubs.com/ quantitative, or contact your UBS sales representative for access to the report or the Quantitative Research Team on ubs-quantanswers@ubs.com. A consolidated report which contains all responses is also available and again you should contact your UBS sales representative for details and pricing or the Quantitative Research team on the email above.